3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neuroendocrine Tumors
13
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
Docetaxel
277
Prednisone
236
enzalutamide
175
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
153
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
78
abiraterone
75
gallium 68 PSMA-11
74
Specimen Handling
67
Gonadotropin-Releasing Hormone
58
darolutamide
56
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
49
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
lanreotide
×
Clear all
NCT01313273
2019-11-22
POSEIDON
Ipsen
Phase 3
Terminated
3 enrolled
4 charts